|
|
Mr. Wasserstein specializes in the areas of healthcare fraud and abuse, pharmaceutical and medical device promotional and marketing issues, health privacy (HIPAA), as well as general food and drug law. He primarily counsels pharmaceutical and medical device companies on compliance issues. Mr. Wasserstein is the co-founding blogger of www.fdalawblog.net and has a special interest in the use of social media tools in the marketing of therapeutic products.
Prior to joining the firm in 2000, Mr. Wasserstein practiced in the areas of food and drug and healthcare law at the Washington, D.C. office of Sidley & Austin. Before entering private practice, he clerked for the Honorable Samuel A. Alito, Jr. of the United States Court of Appeals for the Third Circuit and the Honorable Allyne R. Ross, United States District Judge for the Eastern District of New York. Mr. Wasserstein is a 1996 graduate of Columbia University School of Law and holds Bachelor of Arts degrees from Columbia University and the Jewish Theological Seminary. Mr. Wasserstein is admitted to practice law in the District of Columbia, New York, and New Jersey.
Articles / Publications
Court Empowers Qui Tam Defendants To Sue Third Parties For Indemnification,
February 26, 2010
Application of Health Care Fraud and Abuse Laws to Pharmaceutical Marketing,
January 2009
PhRMA Releases Revised "Code on Interactions with Healthcare Professionals" More Restrictive than July 2002 Version; HPM Issues Summary Memorandum,
July 10, 2008
CMS Final Rule on the Drug Rebate Program,
August 9, 2007
Crossing the Line: Kickbacks Come Under Increased Government Scrutiny,
April 6, 2007
Application Of Health Care Fraud And Abuse Laws To Pharmaceutical Marketing,
September 2006
Medtronic Reaches Settlement over Allegations of Illegal Physician Payments to Promote Spinal Products,
July 18, 2006
New Law Reins in "Authorized Generics" Despite Generic Industry Court Losses, But Leaves Several Ambiguities,
June 2006
New Case Raises Doubts on FDA's Authority to Obtain Restitution and Disgorgement,
May/June 2005
HIPAA and Drug Company Interactions with Physicians - Beyond Clinical Research,
May/June 2003
Western States Medical Center: A Watershed Moment for FDA's Regulation of Commercial Speech,
January/February 2003
FDA's Crackdown on Cholesterol Structure - Function Claims - A Portent of Policies to Come?,
May/June 2001
Sample Promotion Under the New PDMA Final Rules,
January/February, 2000
|
